Cargando…

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

BACKGROUND: Clinicopathological and molecular features of responders to nivolumab for advanced gastric cancer (AGC) are not well understood. METHODS: Patients (pts) with AGC who were treated with nivolumab after two or more chemotherapy regimens in a single institution from September 2017 to May 201...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishima, Saori, Kawazoe, Akihito, Nakamura, Yoshiaki, Sasaki, Akinori, Kotani, Daisuke, Kuboki, Yasutoshi, Bando, Hideaki, Kojima, Takashi, Doi, Toshihiko, Ohtsu, Atsushi, Yoshino, Takayuki, Kuwata, Takeshi, Tsuji, Akihito, Shitara, Kohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357506/ https://www.ncbi.nlm.nih.gov/pubmed/30704511 http://dx.doi.org/10.1186/s40425-019-0514-3

Ejemplares similares

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer
por: Ishii, Takahiro, et al.
Publicado: (2020)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer
por: Sasaki, Akinori, et al.
Publicado: (2020)

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
por: Kawazoe, Akihito, et al.
Publicado: (2020)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials
por: Nagatani, Yoshiaki, et al.
Publicado: (2016)

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
por: Yukami, Hiroki, et al.
Publicado: (2022)

Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
por: Chida, Keigo, et al.
Publicado: (2022)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer
por: Matsumoto, Hiroshi, et al.
Publicado: (2018)

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
por: Tada, Yasuko, et al.
Publicado: (2018)

Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience
por: Kubota, Yohei, et al.
Publicado: (2022)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study
por: Naito, Yoichi, et al.
Publicado: (2018)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2016)

Next-generation sequencing and biomarkers for gastric cancer: what is the future?
por: Kawazoe, Akihito, et al.
Publicado: (2019)

Clinical practice guidance for next‐generation sequencing in cancer diagnosis and treatment (Edition 1.0)
por: Sunami, Kuniko, et al.
Publicado: (2018)

The New Era of Immunotherapy in Gastric Cancer
por: Takei, Shogo, et al.
Publicado: (2022)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
por: Fuchizawa, Hirotaka, et al.
Publicado: (2021)

Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2015)

A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Hypothyroidism and hypopituitarism as immune-related adverse events due to lenvatinib plus pembrolizumab therapy in the immediate postoperative period after laparoscopic hepatectomy for liver metastases from gastric cancer: a case report
por: Sasaki, Kimimasa, et al.
Publicado: (2021)

SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors
por: Nakamura, Yoshiaki, et al.
Publicado: (2021)

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
por: Jogo, Tomoko, et al.
Publicado: (2021)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
por: Bando, H, et al.
Publicado: (2011)

Successful treatment with nivolumab in a patient with lung adenocarcinoma complicated by pulmonary aspergilloma
por: Furuya, Naoki, et al.
Publicado: (2020)

Short-term safety of adjuvant chemoradiotherapy after local resection for patients with high-risk submucosal invasive rectal cancer: a single-arm, multicenter phase II trial
por: Noguchi, Masaaki, et al.
Publicado: (2021)

Protective Effect of Insulin in Mouse Nasal Mucus Against Olfactory Epithelium Injury
por: Kikuta, Shu, et al.
Publicado: (2021)

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
por: Kamada, Takahiro, et al.
Publicado: (2019)

Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma
por: Hatogai, Ken, et al.
Publicado: (2017)

Insulin-Dependent Maturation of Newly Generated Olfactory Sensory Neurons after Injury
por: Kuboki, Akihito, et al.
Publicado: (2021)

Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
por: Shitara, Kohei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6oa403kk8p0k9tiui0fooj6s7a